Gilead and Vir Biotechnology strike a $1.87 billion T-cell engager collaboration, and Fox Rothschild’s Marc Wagner examines what slows manufacturers’ response to rising drug demand and how compounding pharmacies help fill the resulting gaps.
|Podcasts|March 19, 2020
Episode 51: Combating Coronavirus
Author(s)Christen Harm, Elaine Quilici
Dr. Eric von Hofe, Chief Scientific Officer at NuGenerex Immuno-Oncology talks about the recent outbreak of Wuhan coronavirus around the world and how biotechs and pharma are jumping in to help find a solution.
Advertisement
Dr. Eric von Hofe, Chief Scientific Officer at NuGenerex Immuno-Oncology talks about the recent outbreak of Wuhan coronavirus around the world and how biotechs and pharma are jumping in to help find a solution.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Advertisement
Related to this article
Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona Therapeutics’ obesity RNAi candidate while Pfizer partners with Enodia Therapeutics on Sec61 inhibitors, and PaxSafe’s Mark Talens makes the case for acting on imperfect supply chain data.
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a first-line maintenance therapy in HER2-positive breast cancer.
Advertisement
Advertisement
Trending on PharmExec
1
The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble
2
FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease
3
EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe
4
When Experience, Evidence, and AI Disagree in Pharma, What Should Leaders Do?
5